Seroprevalence and risk factors of Hepatitis A virus among Palestinian refugees in North Lebanon: A pilot study to inform vaccination and public health policy Authors: Nagham Said, Nourhan Farhat, Dima El Safadi, Sara Khalife Published: 2026 ABSTRACT AbstractBackgroundHepatitis A virus (HAV) is a vaccine-preventable cause of acute viral hepatitis, transmitted primarily via the fecal–oral route and occasionally leading to severe complications. While Lebanon has experienced major HAV outbreaks in recent years, data on Palestinian refugees remain limited. This study aimed to determine HAV seroprevalence, identify associated risk factors, and assess the potential healthcare burden within this vulnerable population in North Lebanon.MethodsA cross-sectional study was conducted from December 2023 to May 2024, involving 84 systematically selected Palestinian refugees attending Safad Hospital in Al-Baddawi camp, North Lebanon. Socio-demographic and clinical data were collected using standardized questionnaire, and serum samples were tested for IgM and total anti-HAV antibodies.ResultsOverall, 78.6% of participants were seropositive for total anti-HAV antibodies, reflecting accumulated immunity resulting from prior vaccination and/or past natural infection, while 2.4% tested positive for IgM anti-HAV, indicating limited evidence of recent or acute infection at the time of the survey. Multivariable analysis showed that individuals aged 16–30 years were at higher risk of HAV seropositivity (P < 0.05). Vaccination coverage was high (96.4% reported receiving at least one dose), but challenges to achieving universal coverage remain within the broader refugee population.ConclusionsThese findings highlight the continued presence of susceptible individuals, particularly in younger age groups, and support the need for sustained vaccination efforts, improved surveillance, and targeted public health interventions in refugee settings.Keywords: Hepatitis A virus, Palestinian refugees, Seroprevalence, Risk factors, North Lebanon Introduction Hepatitis A virus (HAV), a member of the Picornaviridae family, is a hepatotropic virus with a positive-sense, single-stranded RNA genome of approximately 7500 nucleotides. It is primarily transmitted via the fecal-oral route, either through direct person-to-person contact or the ingestion of contaminated food or water [1]. Notable foodborne outbreaks, such as the Shanghai outbreak linked to contaminated clams, highlight the potential for rapid HAV spread [2], while sewage exposure continues to pose risks even in industrialized countries [3]. Clinically, HAV infection ranges from asymptomatic cases, particularly in children under five years of age, to symptomatic illness in older individuals, including fatigue, vomiting, fever, jaundice, and elevated liver enzymes [4,5]. Although recovery is typically complete within two months and confers lifelong immunity [6], severe complications such as acute liver failure, pancreatitis, and Guillain–Barré syndrome have been reported [7]. Globally, HAV accounts for an estimated 159 million new infections and 4000 deaths annually, with the heaviest burden in sub-Saharan Africa and Asia [8]. In the Middle East and North Africa (MENA) region, HAV remains endemic, with more than 90% of children in some countries seropositive by age ten due to inadequate sanitation [9,10]. Seroprevalence varies widely, from very high levels in Egypt (93.4%) and Syria (89%) [11,12], to lower levels in Saudi Arabia (28.9%) and Kuwait (28.8%) [13,14]. In Lebanon, studies have reported heterogenous seroprevalence across populations, ranging from 29.3% among pediatric patients [15], to over 70% in schoolchildren and blood donors [16,17]. In 2022 and 2023, Lebanon experienced its largest hepatitis A outbreaks in decades, with over 600 cases reported in 2022 and nearly 1800 by August 2023, predominantly among youth and young adults in the North and Bekaa governorates. These outbreaks not only underscore the country's longstanding HAV endemicity but also reflect a documented shift in age-specific seroprevalence, placing adolescents and adults, who are at higher risk of severe illness, at the forefront of current transmission [18]. The recent resurgence of HAV in Lebanon, disproportionately affecting youth and young adults (32.5% of cases aged 10–19 and 29.8% aged 20–39), reflects a regional epidemiological shift attributed to declining childhood IgG seroprevalence. This has resulted in a growing pool of susceptible older children and adults now experiencing more symptomatic and severe infections. Contributing factors include water contamination, infrastructure deterioration, and the mixing of potable water with sewage, issues exacerbated by Lebanon's ongoing economic collapse and rapid population displacement [18]. Lebanon is currently undergoing one of the world's most profound socio-economic crises while hosting the highest number of refugees per capita [19]. Palestinian refugee camps in Lebanon are overcrowded and suffer from limited access to water, sanitation, and healthcare services, conditions that facilitate viral transmission [20]. Approximately 93% of Palestinians in Lebanon live in poverty, facing significant barriers to employment, healthcare, and secure housing [21]. Given that Palestine is classified as a high-endemic country for HAV [22], displaced populations residing in crowded camps represent a high-risk group for future outbreaks [23]. Despite numerous HAV-related studies in Lebanon, little is known about its epidemiology among Palestinian refugees. Addressing this gap is critical for designing targeted vaccination strategies and enhancing outbreak preparedness within Lebanon's fragile healthcare system, particularly in the context of recent epidemics and shifting immunity profiles. Therefore, this study aimed to determine HAV seroprevalence among Palestinian refugees in North Lebanon, identify associated risk factors, and assess the implications for vaccination policy and healthcare system resilience, given that this population is at the epicenter of current national trends. Methods Study design and population A cross-sectional study was conducted between December 2023 and May 2024 at the phlebotomy unit of Safad Hospital, located within the Beddawi Camp in North Lebanon. This period coincided with a documented seasonal increase in hepatitis A virus (HAV) cases in Lebanon [24], enhancing the relevance of the seroprevalence data to ongoing epidemiological trends. The Beddawi Camp spans approximately one square kilometer and hosts over 20,866 registered refugees [25]. Safad Hospital primarily serves the Palestinian refugee population residing in the camp, with additional patients from the nearby Nahr al-Bared Camp, as well as a minority of Lebanese and Syrian nationals. Sample size calculation The minimum required sample size was calculated using the single population proportion formula for cross-sectional studies. Assuming a 95% confidence level, an expected HAV seroprevalence of 90% based on previous regional data, and a margin of error of 5%, the initial calculated sample size was 138 participants. However, due to feasibility constraints and the number of eligible attendees during the study period, a total of 84 participants were ultimately recruited. Sampling procedure Due to the absence of a comprehensive daily patient registry, a systematic sampling method was employed. On each data collection day, a random starting point was selected among eligible attendees at the phlebotomy unit, after which every second eligible patient was approached for participation. The sampling interval was determined by dividing the estimated number of eligible patients attending the phlebotomy unit during the study period (approximately 320), obtained from clinic attendance records and laboratory registers, by the target sample size (138), resulting in a sampling interval of two. Consequently, every second eligible patient was invited to participate following the selection of a random starting point. Patients who met the eligibility criteria and provided informed consent were enrolled. This systematic approach was used to reduce selection bias and ensure recruitment was distributed across the study period. Eligible participants were Palestinian refugees aged ≥4 years, permanent residents of Beddawi or Nahr al-Bared camps, and willing to provide informed consent (or parental consent for minors). Exclusion criteria included the presence of acute febrile illness at the time of sample collection and a known diagnosis of chronic liver disease not related to hepatitis A infection. Data and sample collection Data were collected using a standardized questionnaire administered by trained personnel. It included socio-demographic characteristics, clinical symptoms, and HAV risk factors such as hygiene practices, water source, food behaviors, animal contact, travel history, and self-reported or documented vaccination. The questionnaire was pre-tested on 10 participants. After each interview, venous blood was collected in clot activator tubes, labeled with anonymized identifiers, and transported to the Biomedical Laboratory at Beirut Arab University. Samples were centrifuged at 3500 rpm for 10 min, and serum was stored at −20°C until analysis. Serological testing Serological analyses were performed using enzyme-linked immunosorbent assays (ELISA) (DRG International Inc., USA), following the manufacturer's protocols. Total anti-HAV antibodies were detected using a competitive ELISA, while IgM anti-HAV antibodies were measured using a capture ELISA. Detection was based on horseradish peroxidase (HRP)-conjugated HAV antigens, and results were interpreted using the manufacturer's recommended cut-off values (0.9 for total anti-HAV and 0.8 for IgM anti-HAV). Each test batch included appropriate positive and negative controls. Borderline results were retested in duplicate to ensure accuracy. Optical density (OD) values were measured using a microplate ELISA reader (Huma Reader HM, Human GmbH, Wiesbaden, Germany). Statistical analysis Statistical analyses were conducted using IBM Statistical Packages for Social Sciences (IBM SPSS, version 22.00, IBM Corp., Armonk, N.Y., USA). Associations between categorical variables were assessed using the Chi-square test or Fisher's exact test, as appropriate. Odds ratios (OR) with 95% confidence intervals (CI) were calculated to estimate the strength of associations. Multivariable logistic regression analysis was performed to identify independent predictors of total anti-HAV seropositivity. Variables with a P-value <0.25 in the univariate analysis were considered for inclusion in the multivariable model. The final model was evaluated using the Hosmer–Lemeshow goodness-of-fit test. A P-value <0.05 was considered statistically significant. Missing data (<5%) were excluded from the analysis. In contrast, multivariable logistic regression was not performed for IgM anti-HAV seropositivity due to the very low number of positive cases and the sparse distribution of several covariates, which resulted in model instability and unreliable parameter estimates. Accordingly, IgM outcomes were analyzed using descriptive statistics and univariate analyses only. Ethical statement The study was conducted in accordance with the ethical principles outlined in the World Medical Association's Declaration of Helsinki. Ethical approval was obtained from the Institutional Review Board (IRB) of Beirut Arab University (IRB No. 2023-H-0143-HS-M-0503). Written informed consent was obtained from all participants prior to their enrollment in the study. For individuals under 18 years of age, informed consent was obtained from a parent or legal guardian, with assent from the minor when applicable. Results A total of 84 participants were enrolled in this study, including 45 females (53.6%) and 39 males (46.4%). The age distribution was as follows: 10 participants (11.9%) were under 15 years of age, 28 (33.3%) were between 16 and 31 years, and 46 (54.8%) were over 31 years. Regarding marital status, 29 participants (34.5%) were single, while 55 (65.5%) were married. Educational attainment was classified as high in 33 participants (39.3%) and low to intermediate in 51 participants (60.7%) (Table 1). Table 1Socio-demographic characteristics of the study population and their associations with IgM and total anti-HAV antibodies.Table 1VariableTotal count n(%)Positive total anti-HAV antibodies n(%)Negative total anti-HAV antibodies n(%)PPositive IgM anti-HAV n(%)Negative IgM anti-HAV n(%)PELISA results8466 (78.6%)18 (21.4%)-2 (2.4%)82 (97.6%)-Gender0.8490.213Male39 (46.4%)31 (47.0%)8 (44.4%)2 (100%)37 (45.1%)Female45 (53.6%)35 (53.0%)10 (55.6%)0 (0%)45 (54.9%)Age groups<0.001*1<15 years old10 (11.9%)6 (9.1%)4 (22.2%)0 (0%)10 (12.2%)16-30 years28 (33.3%)16 (24.2%)12 (66.7%)1 (50.0%)27 (32.9%)>3146 (54.8%)44 (66.7%)2 (11.1%)1 (50.0%)45 (54.9%)Marital status<0.001*0.116Single29 (34.5%)16 (24.2%)13 (72.2%)2 (100%)27 (32.9%)Married55 (65.5%)50 (75.8%)5 (27.8%)0 (0%)55 (67.1%)Level of education0.1111High33 (39.3%)23 (34.8%)10 (55.6%)1 (50.0%)32 (39.0%)low/Intermediate51 (60.7%)43 (65.2%)8 (44.4%)1 (50.0%)50 (61.0%)*: Significant.Level of education: High-level education was defined as university or above, whereas low/intermediate education referred to secondary school or below. Socio-demographic characteristics of the study population and their associations with IgM and total anti-HAV antibodies. *: Significant. Level of education: High-level education was defined as university or above, whereas low/intermediate education referred to secondary school or below. The overall seroprevalence of total anti-HAV antibodies, indicative of prior exposure or immunity, was 78.6% (66/84). In contrast, IgM anti-HAV antibodies, suggestive of recent or acute infection, were detected in two participants (2.4%) (Table 1). Both IgM-positive cases occurred in males under 30 years of age. One was a 21-year-old active smoker with a high educational level, while the other was a 27-year-old participant with a low-to-intermediate educational level receiving thyroid hormone therapy. Both individuals reported severe headache at the time of sample collection. Vaccination coverage was high, with 96.4% (81/84) reporting receipt of at least one dose of the HAV vaccine. Among vaccinated participants, seropositivity for total anti-HAV antibodies was also high (95.5%, 63/66), although the difference in seroprevalence between vaccinated and unvaccinated individuals was not statistically significant. Notably, both IgM-positive cases occurred equally among vaccinated and unvaccinated individuals (Table 2). Table 2Medication use and vaccination status of the study population and their associations with IgM and total anti-HAV antibodies.Table 2VariableTotal count n(%)Positive total anti-HAV antibodies n(%)Negative total anti-HAV antibodies n(%)PPositive IgM anti-HAV n(%)Negative IgM anti-HAV n(%)PMetformin hydrochloride0.5801Yes5 (6.0%)5 (7.6%)0 (0%)0 (0%)5 (6.1%)No79 (94.0%)61 (92.4%)18 (100%)2 (100%)77 (93.9%)Bisoprolol fumarate0.0611Yes12 (14.3%)12 (18.2%)0 (0%)0 (0%)12 (14.6%)No72 (85.7%)54 (81.8%)18 (100%)2 (100%)70 (85.4%)Levothyroxine10.139Yes6 (7.1%)5 (7.6%)1 (5.6%)1 (50.0%)5 (6.1%)No78 (92.9%)61 (92.4%)17 (94.4%)1 (50.0%)77 (93.9%)Vaccinated against HAV (1st dose)10.071Yes81 (96.4%)63 (95.5%)18 (100%)1 (50.0%)80 (97.6%)No3 (3.6%)3 (4.5%)0 (0%)1 (50.0%)2 (2.4%)Vaccinated against HAV (2nd dose)10.071Yes81 (96.4%)63 (95.5%)18 (100%)1 (50.0%)80 (97.6%)No3 (3.6%)3 (4.5%)0 (0%)1 (50.0%)2 (2.4%) Medication use and vaccination status of the study population and their associations with IgM and total anti-HAV antibodies. A statistically significant association was observed between total anti-HAV seropositivity and both age group and marital status (P < 0.001) (Table 1). No significant associations were identified between total anti-HAV seropositivity and therapeutic drug use, travel history, or disease status (Table 2, Table 3) (see Table 4). Table 3Clinical Symptoms and comorbidities of the study population and their associations with IgM and total anti-HAV antibodies.Table 3VariableTotal count n(%)Positive total anti-HAV antibodies n(%)Negative total anti-HAV antibodies n(%)PPositive IgM anti-HAV n(%)Negative IgM anti-HAV n(%)PFever0.4400.225Yes10 (11.9%)7 (10.6%)3 (16.7%)1 (50.0%)9 (11.0%)No74 (88.1%)59 (89.4%)15 (83.3%)1 (50.0%)73 (89.9%)Nausea10.060Yes21 (25.0%)17 (25.8%)4 (22.2%)2 (100%)19 (23.2%)No63 (75.0%)49 (74.2%)14 (77.8%)0 (0%)63 (76.8%)Diarrhea0.6040.139Yes6 (7.1%)4 (6.1%)2 (11.1%)1 (50.0%)5 (6.1%)No78 (92.9%)62 (93.9%)16 (88.9%)1 (50.0%)77 (93.9%)Vomiting0.4471Yes12 (14.3%)11 (16.7%)1 (5.6%)0 (0%)12 (14.6%)No72 (85.7%)55 (83.3%)17 (94.4%)2 (100%)70 (85.4%)Headache0.1340.073Yes23 (27.4%)21 (31.8%)2 (11.1%)2 (100%)21 (25.6%)No61 (72.6%)45 (68.2%)16 (88.9%)0 (0%)61 (74.4%)Abdominal pain0.4400.225Yes10 (11.9%)7 (10.6%)3 (16.7%)1 (50.0%)9 (11.0%)No74 (88.1%)59 (89.4%)15 (83.3%)1 (50.0%)73 (89.0%)Diabetes0.3371Yes7 (8.3%)7 (10.6%)0 (0%)0 (0%)7 (8.5%)No77 (91.7%)59 (89.4%)18 (100%)2 (100%)75 (91.5%)High blood pressure0.1730.347Yes16 (19.0%)15 (22.7%)1 (5.6%)1 (50.0%)15 (18.3%)No68 (81.0%)51 (77.3%)17 (94.4%)1 (50.0%)67 (81.7%)Hypercholesteremia0.4431Yes11 (13.1%)10 (15.2%)1 (5.6%)0 (0%)11 (13.4%)No73 (86.9%)56 (84.8%)17 (94.4%)2 (100%)71 (86.6%) Clinical Symptoms and comorbidities of the study population and their associations with IgM and total anti-HAV antibodies. Table 4Lifestyle-related characteristics of the study population and their associations with IgM and total anti-HAV antibodies.Table 4VariableTotal count n(%)Positive total anti-HAV antibodies n(%)Negative total anti-HAV antibodies n(%)PPositive anti-HAV IgM n(%)Negative anti-HAV IgM n(%)PTravel history0.4970.542Yes (Asia and Europe)32 (36.0%)24 (36.4%)5 (27.8%)0 (0%)29 (35.4%)No42 (63.6%)42 (63.6%)13 (72.2%)2 (100%)53 (64.6%)Water supply0.6390.523Community tap water52 (61.9%)40 (60.6%)12 (66.7%)2 (100%)50 (61.0%)Hand pumps well32 (38.1%)26 (39.4%)6 (33.3%)0 (0%)32 (39.0%)Contact with Domestic animals0.7291Yes15 (17.9%)11 (16.7%)4 (22.2%)0 (0%)15 (18.3%)No69 (82.1%)55 (83.3%)14 (77.8%)2 (100%)67 (81.7%)Exposure to untreated sewage0.5801Yes5 (6.0%)5 (7.6%)0 (0%)0 (0%)5 (6.1%)No79 (94.0%)61 (92.4%)18 (100%)2 (100%)77 (93.9%)Shisha intake11Yes11 (13.1%)9 (13.6%)2 (11.1%)0 (0%)11 (13.4%)No73 (86.9%)57 (56.4%)16 (88.9%)2 (100%)71 (76.6%)Smoking habit0.032*0.403Passive smokers3 (3.6%)2 (3.0%)1 (5.6%)0 (0%)3 (3.7%)Active smokers16 (19.0%)16 (24.2%)0 (0%)1 (50.0%)15 (18.3%)Nonsmokers65 (77.4%)48 (72.7%)17 (94.4%)1 (50.0%)64 (78.0%)Steak consumption10.287Yes71 (84.5%)56 (84.8%)15 (83.3%)1 (50.0%)70 (85.4%)No13 (15.5%)10 (15.2%)3 (16.7%)1 (50.0%)12 (14.6%)Liver sausage consumption0.9030.542Yes57 (67.9%)45 (68.2%)12 (66.7%)1 (50.0%)56 (68.3%)No27 (32.1%)21 (31.8%)6 (33.3%)1 (50.0%)26 (91.7%)Raw vegetables consumption11Yes81 (96.4%)63 (95.5%)18 (100%)2 (100%)79 (96.3%)No3 (3.6%)3 (4.5%)0 (0%)0 (0%)3 (3.7%)Raw fruits consumption11Yes81 (96.4%)63 (95.5%)18 (100%)2 (100%)79 (96.3%)No3 (3.6%)3 (4.5%)0 (0%)0 (0%)3 (3.7%)*: Significant. Lifestyle-related characteristics of the study population and their associations with IgM and total anti-HAV antibodies. *: Significant. In the multivariable logistic regression analysis, age group remained significantly associated with total anti-HAV seropositivity. Participants aged 16–30 years had significantly different odds of seropositivity compared with the reference group (OR = 21.516, 95% CI: 1.513–306.086; P = 0.023), whereas no other variables remained significantly associated after adjustment for potential confounders (P > 0.05) (Table 5). Overall, seropositivity increased with age, reaching the highest levels among participants older than 30 years, while younger age groups exhibited lower seroprevalence and consequently greater susceptibility to HAV infection. Table 5Multivariable logistic regression analysis of factors associated with total anti-HAV seropositivity.Table 5VariablePositive total anti-HAV antibodies n(%)Negative total anti-HAV antibodies n(%)Odds ratio95% CIPAge groups>15 years old6 (9.1%)4 (22.2%)16.2530.638-414.2180.09116-30 years16 (24.2%)12 (66.7%)21.5161.513-306.0860.023*31 and over (Reference)44 (66.7%)2 (11.1%)---Marital statusSingle16 (24.2%)13 (72.2%)3.1710.532-18.9240.205Married (Reference)50 (75.8%)5 (27.8%)---Level of educationHigh23 (34.8%)10 (55.6%)1.2740.276-5.8810.756Low/intermediate (Reference)43 (65.2%)8 (44.4%)---Bisoprolol fumarateYes12 (18.2%)0 (0%)000.999No (Reference)54 (81.8%)18 (100%)---HeadacheYes (Reference)21 (31.8%)2 (11.1%)---No45 (68.2%)16 (88.9%)4.6040.676-31.3750.119High blood pressureYes (Reference)15 (22.7%)1 (5.6%)---No51 (77.3%)17 (94.4%)0.1680.006-4.7450.295Smoking habitPassive smokers2 (3.0%)1 (5.6%)7.5950.260-222.0770.239Active smokers16 (24.2%)0 (0%)000.998Nonsmokers (Reference)48 (72.7%)17 (94.4%)---*: Significant.CI: Confidence Interval. Multivariable logistic regression analysis of factors associated with total anti-HAV seropositivity. *: Significant. CI: Confidence Interval. With respect to IgM anti-HAV antibodies, no statistically significant associations were observed with any of the variables examined. Given the very small number of IgM-positive cases, these findings should be interpreted with caution. Discussion The global burden of Hepatitis A virus (HAV) infection continues to pose a significant public health challenge, with outbreaks reported across various regions. Notably, Canada and Europe experienced outbreaks during 2012–2013 [26,27], while more recent events in early 2025 have affected Austria, Czechia, Hungary, and Slovakia, resulting in over 2000 reported cases [28]. These incidents highlight the persistent public health importance of HAV and emphasize the need to better understand population-level immunity within vulnerable groups. This study provides a novel assessment of HAV exposure and immunity among Palestinian refugees in North Lebanon, a vulnerable and under-studied population. A total anti-HAV seroprevalence of 78.6% indicates high seropositivity likely reflecting either prior vaccination or past natural exposure, which represents background immunity at the population level rather than direct evidence of current protection against future outbreaks, while 2.4% IgM positivity suggests limited but ongoing viral circulation and reflects a low level of recent or acute infection within the study sample at the time of data collection. Recent surveillance data from Lebanon reveal a resurgence of HAV, with over 600 reported cases in 2022, predominantly affecting youth and young adults aged 10–39 years, particularly in the North and Bekaa governorates [29]. This re-emergence corresponds with a documented decline in IgG anti- HAV seroprevalence among children nationally, reflecting a shift in transmission dynamics that increases susceptibility among older adolescents and adults who are at greater risk of symptomatic infection [16,30]. Our findings among Palestinian refugees are consistent with this epidemiological trend. Importantly, the age distribution of seropositivity observed in our cohort, characterized by lower immunity in younger age groups and higher seropositivity in older individuals, closely mirrors the pattern reported in recent HAV outbreaks in North Lebanon, suggesting that refugees and the surrounding host community are likely influenced by the same regional transmission dynamics. Comparatively, our results align with broader seroprevalence patterns reported across the MENA region, with seroprevalence levels intermediate between those observed in Yemen (86.6%) and Egypt (100%) [31,32], and substantially higher than levels reported in Kuwait (28.6%) [14]. Among Palestinian refugees, seroprevalence exceeds estimates reported in Lebanese blood donors (72.0%) [17] and schoolchildren [33], underscoring the burden of HAV antibodies within this population, although these findings cannot distinguish between vaccine-induced immunity and past natural infection. These disparities are further exacerbated by Lebanon's ongoing socioeconomic crisis, deteriorating public health infrastructure, and limited access to routine HAV vaccination at the national population level. When compared to available national data from North Lebanon, where recent outbreaks have primarily affected younger age groups, our findings suggest a broadly similar epidemiological pattern between Palestinian refugees and the host community, particularly in terms of age-related susceptibility [16,30]. However, direct comparisons remain limited due to the lack of contemporaneous, population-based seroprevalence studies in the surrounding Lebanese host population. Vaccination coverage within this cohort was notably high, with over 96% of participants reporting receipt of at least one dose of the hepatitis A vaccine reflecting immunization status among individuals attending a hospital-based refugee clinic setting rather than population-level coverage estimates. This finding should be interpreted with caution, as vaccination status was self-reported and not independently verified through complete immunization records, which may introduce recall or reporting bias. This high reported coverage likely reflects ongoing immunization efforts targeting displaced and refugee populations [34,35]. Despite this high coverage, recent HAV infections (IgM positive) were observed among both vaccinated and unvaccinated individuals. The equal distribution of IgM positivity between vaccinated and unvaccinated groups should be interpreted cautiously due to the small number of unvaccinated participants and the low incidence of recent infections. Larger longitudinal studies with verified vaccination histories and immunological follow-up are needed to better characterize vaccine-derived protection and infection dynamics in this population [34,35]. The statistically significant association between age and total anti-HAV seropositivity observed in our cohort aligns with global epidemiological shifts in HAV endemicity. Improvements in sanitation and reduced early childhood viral exposure have resulted in a shift of seroconversion toward older age groups, consequently increasing the risk of severe disease during adolescence and adulthood [16,36]. Our findings demonstrate an age-related increase in HAV seropositivity, with lower immunity levels observed among children and young adults. This pattern suggests greater susceptibility to HAV infection in individuals younger than 30 years and is consistent with the epidemiological shift reported in Lebanon and other countries undergoing transitions from high to intermediate endemicity [16,36]. Despite the low IgM seroprevalence suggesting limited evidence of active transmission within the study sample at the time of investigation, the persistent vulnerability of refugee populations remains a significant concern due to overcrowding, inadequate sanitation, and constrained access to healthcare. The potential for rapid HAV outbreaks should not be underestimated, especially in settings where vaccination coverage remains suboptimal and water and sewage infrastructure is compromised [37]. No significant associations were identified between HAV seropositivity and gender, education, smoking status, or other lifestyle factors, likely reflecting the dominant influence of age, endemic exposure, and the limited sample size [38]. In conclusion, our findings highlight a high level of total anti-HAV antibody prevalence in this population, most plausibly reflecting vaccination-induced immunity or past exposure, representing accumulated immunity rather than evidence of current transmission dynamics or outbreak control effectiveness in isolation. While continued vigilance is warranted, particularly in high-risk subgroups, the data do not support an increased burden of acute infection or the need for intensified vaccination campaigns beyond maintaining and sustaining existing programs. Sustained collaboration among the United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA), local healthcare providers, non-governmental organizations, and governmental authorities will be critical to consolidate progress in HAV control and protect the health of refugee populations in Lebanon and other comparable high-risk settings globally. Limitations This study has several limitations. The relatively small sample size may limit statistical power and reduce the generalizability of the findings to the wider refugee camp population. In addition, the study is hospital-based and includes only individuals attending the phlebotomy unit of Safad Hospital; therefore, it may not be fully representative of the broader community and is subject to selection bias inherent to facility-based recruitment. The cross-sectional design captures data at a single time point, which limits the assessment of temporal trends and precludes causal inference. Accordingly, larger longitudinal studies are needed to better characterize the epidemiology of hepatitis A virus over time. Furthermore, self-reported vaccination status may be subject to recall or reporting bias, particularly in the absence of complete immunization record verification. In addition, the serological assay used cannot differentiate between vaccine-induced and infection-induced IgG antibodies, which limits interpretation of immunity sources within the study population. Finally, the small number of IgM-positive cases precludes meaningful statistical comparison between vaccinated and unvaccinated groups, and these findings should therefore be interpreted descriptively with caution. Addressing these limitations in future research will enhance understanding of HAV transmission dynamics in displaced populations and support the development of more targeted public health interventions. Conclusion This study offers important data on Hepatitis A among Palestinian refugees in North Lebanon. The high total anti-HAV seroprevalence reflects accumulated immunity in the population, likely resulting from a combination of prior vaccination and past natural exposure, rather than a direct indicator of current transmission patterns, shaped by crowded living conditions, limited healthcare access, uneven vaccination, and persistent environmental risks in refugee camps. The low prevalence of IgM anti-HAV antibodies suggests limited evidence of active or recent infection at the time of this cross-sectional assessment, rather than sustained ongoing transmission, and should be interpreted within the constraints of a single time-point survey. Sustaining progress requires addressing persistent risk factors, strengthening targeted vaccination for high-risk groups, and improving sanitation and healthcare services. These steps are especially vital amid rising hepatitis A cases in Lebanon, which disproportionately affect displaced populations. Overall, integrated public health strategies remain essential for protecting vulnerable communities in Lebanon and beyond. Ethical statement The study was conducted in accordance with the ethical principles outlined in the World Medical Association's Declaration of Helsinki. Ethical approval was obtained from the Institutional Review Board (IRB) of Beirut Arab University (IRB No. 2023-H-0143-HS-M-0503). Written informed consent was obtained from all participants prior to their enrollment in the study. Declaration of generative AI and AI-assisted technologies in the writing process During the preparation of this work the authors used ChatGPT in order to improve language and readability of the manuscript. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. CRediT authorship contribution statement Nagham Said: Data curation, Investigation, Visualization, Writing – original draft, Writing – review & editing. Nourhan Farhat: Data curation, Investigation, Visualization, Writing – original draft, Writing – review & editing. Dima El Safadi: Conceptualization, Methodology, Project administration, Validation, Writing – review & editing. Sara Khalife: Conceptualization, Methodology, Project administration, Validation, Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgements The authors would like to extend their sincere gratitude to the personnel of Safad Hospital for their collaboration and valuable assistance in the collection of samples. Abbreviations The following abbreviations are used in this manuscript: HAVHepatitis A VirusELISAEnzyme-Linked Immunosorbent AssaysUNRWAUnited Nations Relief and Works Agency for Palestine Refugees in the Near EastMENAMiddle East and North Africa References